HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Increase of estrogen dose deteriorates mood during progestin phase in sequential hormonal therapy.

Abstract
Previous studies have indicated that the addition of progestins during sequential hormonal replacement therapy (HRT) causes negative mood and physical symptoms. History of premenstrual syndrome, type of progestin, and dose of progestin have thus far been shown to influence the progestin-induced adverse mood symptoms during HRT. The aim of this study was to compare adverse mood effects of two different doses of estradiol, in combination with a progestin, during postmenopausal HRT. Twenty-eight perimenopausal women were included in this randomized, double-blind, crossover study comparing 2- or 3-mg continuous estradiol, with an addition of 10 mg medroxyprogesterone acetate on d 17-28 during each treatment cycle. The main outcome measures were mood and physical symptoms kept on a daily rating scale. Together with the progestin, the higher dose of estrogen caused significantly more negative mood symptoms than the lower dose. Tension, irritability, and depressed mood were all significantly augmented during the progestin phase of cycles with 3 mg estradiol (P < 0.001). Physical symptoms also increased during the progestin phase of 3-mg estradiol cycles (P < 0.001), whereas positive mood symptoms were less affected. The only positive mood that changed with estrogen dose was friendliness, which decreased during the progestin phase of high estradiol cycles compared with cycles with lower estradiol (P < 0.05). Our conclusion is that an increase of the estrogen dose accentuates negative mood and physical symptoms during the progestin phase of sequential hormonal therapy.
AuthorsInger Björn, Inger Sundström-Poromaa, Marie Bixo, Sigrid Nyberg, Gunnel Bäckström, Torbjörn Bäckström
JournalThe Journal of clinical endocrinology and metabolism (J Clin Endocrinol Metab) Vol. 88 Issue 5 Pg. 2026-30 (May 2003) ISSN: 0021-972X [Print] United States
PMID12727949 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Estradiol
  • Medroxyprogesterone Acetate
Topics
  • Adult
  • Affect (drug effects)
  • Cross-Over Studies
  • Depression (chemically induced)
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Drug Interactions
  • Estradiol (administration & dosage, adverse effects)
  • Estrogen Replacement Therapy (methods)
  • Female
  • Humans
  • Irritable Mood (drug effects)
  • Medroxyprogesterone Acetate (administration & dosage)
  • Middle Aged

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: